Last updated 7 months ago
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
282 patients around the world
Available in Spain, Argentina, United States
GlaxoSmithKline
3Research sites
282Patients around the world
This study is for people with
Alzheimer disease
Requirements for the patient
To 85 Years
All Gender
Medical requirements
StudyPROGRESS-AD
SponsorGlaxoSmithKline
Conditions
Alzheimer disease
Requirements
To 85 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06079190
